Popular filter options for cidp trials
Cidp Clinical Trials With No Placebo
View 11 cidp medical studies that do not have a placebo group.
Monoclonal Antibodies
SAR445088 for Chronic Inflammatory Demyelinating Polyneuropathy
This trial is testing the efficacy and safety of SAR445088 in CIDP patients. There are three groups of patients: those who are currently being treated with the standard of care (SOC-Treated), those who are refractory to SOC (SOC-Refractory), and those who have never been treated with SOC (SOC-Naive). The secondary objectives are to assess the long-term safety and tolerability of SAR445088 in CIDP patients, as well as the durability of its efficacy over time.
Immunoglobulin
IgPro10 Dosage for Childhood CIDP
This trial is testing two different doses of a medication for kids with a rare disease called CIDP. The trial is open to kids who haven't tried this medication before, and also to kids who have tried it before but at a different dose.
Immunoglobulin
Immune Globulin 10% Intravenous Solution for Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a treatable form of peripheral neuropathy with suspected autoimmune cause. The current first-line treatment is IVIG (immune globulin), which is infused in a set regimen that requires 4-5 hours in a hospital day unit, taking up resources such as nursing time and hospital space. Chronic treatment is required in most cases.
Frequently Asked Questions
Introduction to cidp
What are the top hospitals conducting cidp research?
When it comes to research and clinical trials for chronic inflammatory demyelinating polyneuropathy (CIDP), hospitals across the United States are making strides in advancing our understanding of this complex neurological condition. In New Brunswick, Rutgers, The State University of New jersey Clinical Research Center is at the forefront with their active CIDP trial, marking a significant step forward in finding effective treatment options. Similarly, sites like Number -1600 in Boca Raton, Site Number -1601 in Austin, Site Number -1617 in Ormond Beach, and Site Number -1620 in Port Charlotte are dedicated to conducting vital CIDP trials as well. Collectively recording their first CIDP trials in 2022, these institutions demonstrate an unwavering commitment to researching new therapies and potential breakthroughs for individuals living with CIDP.
CIDP is a rare autoimmune disorder that affects the peripheral nervous system and can cause progressive weakness and sensory abnormalities. It occurs when the body's immune system mistakenly attacks the myelin sheath surrounding nerve fibers. This disruption leads to impaired nerve signal transmission and results in symptoms such as muscle weakness, numbness or tingling sensations, difficulty walking or moving limbs properly.
The location of these hospitals also plays a role in fostering medical advancements for CIDP patients. From the bustling city of New Brunswick to sunny Florida destinations like Boca Raton, Austin, Ormond Beach,and Port Charlotte—these diverse locations allow individuals from different regions access to cutting-edge research opportunities closer to home.
With each hospital dedicating resources towards investigating this rare condition through clinical trials,new insights will be gained that may ultimately lead us closer to more effective treatments and improved quality of life for those living with CIDP
Which are the best cities for cidp clinical trials?
For those seeking CIDP clinical trials, several cities offer promising opportunities for participation. Tampa, Florida leads the way with 5 active studies investigating treatments like SOC-Refractory Initial Dose and Efgartigimod PH20 SC. Boca Raton, Florida follows closely with 3 ongoing trials focusing on interventions such as Efgartigimod PH20 SC and Treatment Period 1: Cohort A, Dose 2. Furthermore, Los Angeles, California; Kansas City, Kansas; and New york, New York each provide access to 3 active trials exploring various treatment options including Nipocalimab and SOC-Refractory Initial Dose. These cities serve as beacons of hope for individuals seeking innovative solutions in CIDP research.
Which are the top treatments for cidp being explored in clinical trials?
Exciting breakthroughs in clinical trials are shedding light on the top treatments being explored for CIDP (chronic inflammatory demyelinating polyneuropathy). Intravenous immune globulin G, Nipocalimab, and Efgartigimod PH20 SC have emerged as promising contenders. Intravenous immune globulin G is currently under investigation in one active trial since its introduction in 2022. Similarly, Nipocalimab and Efgartigimod PH20 SC are each engaged in one ongoing CIDP trial, with a shared debut year of 2022 and showing great potential for promoting positive outcomes among patients suffering from this debilitating condition.
What are the most recent clinical trials for cidp?
The field of CIDP (chronic inflammatory demyelinating polyneuropathy) clinical trials is constantly evolving, offering new possibilities for patients. Recent studies have explored various treatment approaches to address the complexities of this condition. Promising advancements include the investigation of Nipocalimab, an innovative therapeutic option that has progressed into Phase 3 trials after showing potential in Phase 2. Additionally, intravenous immune globulin G has been evaluated in Phase 1 trials as a potential treatment avenue for CIDP. These developments bring hope to individuals living with CIDP by providing them with access to cutting-edge interventions and renewed prospects for improved quality of life.
What cidp clinical trials were recently completed?
Several recent clinical trials have made significant strides in the field of chronic inflammatory demyelinating polyneuropathy (CIDP), a debilitating neurological disorder. Notably, argenx sponsored a trial investigating efgartigimod PH20 SC in stage B, which concluded in April 2020. Additionally, Shire (now part of Takeda) completed two HYQVIA trials for CIDP treatment, one in December 2016 and another prior to that in December 2015. These advancements highlight ongoing efforts to improve therapeutic options and enhance the lives of those living with CIDP.